Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,001.40 -70.23 (-1.38%) Dow
37,779.79 -681.13 (-1.77%) Nasdaq
15,438.48 -274.27 (-1.75%) Bitcoin USD
63,369.05 -1,852.91 (-2.84%) CMC Crypto 200
1,374.35 -8.22 (-0.59%)
Rigel Pharmaceuticals, Inc. (RIGL)
| Previous close | 1.1250 |
| Open | 1.1200 |
| Bid | 1.0800 x 200 |
| Ask | 1.1200 x 400 |
| Day's range | 1.0900 - 1.1300 |
| 52-week range | 0.7100 - 1.9600 |
| Volume | |
| Avg. volume | 1,446,687 |
| Market cap | 191.191M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.57 |
ZacksSilence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
PR NewswireRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 407,325 stock options to nine non-executive employees on April 4, 2024, and 187,500 stock options to Lisa Rojkjaer, Rigel's Chief
- PR Newswire
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
